Capital Investment Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$25.2M Sell
27,421
-11
-0% -$11.2K 0.37% 71
2025
Q4
$29.5M Sell
27,432
-308
-1% -$295K 0.45% 59
2025
Q3
$21.2M Sell
27,740
-123
-0.4% -$91.5K 0.35% 71
2025
Q2
$21.7M Buy
27,863
+267
+1% +$207K 0.39% 68
2025
Q1
$22.8M Buy
27,596
+1,076
+4% +$895K 0.45% 63
2024
Q4
$20.5M Buy
26,520
+1,292
+5% +$1.07M 0.42% 63
2024
Q3
$22.4M Sell
25,228
-393
-2% -$353K 0.46% 61
2024
Q2
$23.2M Sell
25,621
-433
-2% -$346K 0.52% 58
2024
Q1
$20.3M Sell
26,054
-220
-0.8% -$157K 0.47% 62
2023
Q4
$15.3M Buy
26,274
+27
+0.1% +$15.8K 0.38% 69
2023
Q3
$14.1M Buy
+26,247
New +$13.5M 0.39% 68
2023
Q2
Sell
-27,547
Closed -$9.46M 583
2023
Q1
$9.46M Sell
27,547
-1,021
-4% -$344K 0.28% 84
2022
Q4
$10.5M Sell
28,568
-892
-3% -$316K 0.32% 77
2022
Q3
$9.53M Sell
29,460
-352
-1% -$112K 0.33% 77
2022
Q2
$9.67M Sell
29,812
-208
-0.7% -$62.4K 0.32% 77
2022
Q1
$8.6M Buy
30,020
+230
+0.8% +$59.2K 0.26% 85
2021
Q4
$8.23M Buy
29,790
+131
+0.4% +$33.2K 0.25% 83
2021
Q3
$6.85M Sell
29,659
-445
-1% -$110K 0.23% 89
2021
Q2
$6.91M Buy
30,104
+983
+3% +$197K 0.24% 86
2021
Q1
$5.44M Sell
29,121
-846
-3% -$165K 0.2% 94
2020
Q4
$5.06M Sell
29,967
-551
-2% -$82.3K 0.21% 93
2020
Q3
$4.52M Sell
30,518
-54
-0.2% -$8.36K 0.22% 94
2020
Q2
$5.02M Sell
30,572
-318
-1% -$48.8K 0.26% 83
2020
Q1
$4.29M Sell
30,890
-986
-3% -$135K 0.27% 80
2019
Q4
$4.19M Sell
31,876
-82
-0.3% -$9.51K 0.2% 108
2019
Q3
$3.57M Sell
31,958
-132
-0.4% -$14.7K 0.19% 112
2019
Q2
$3.56M Sell
32,090
-841
-3% -$99K 0.2% 106
2019
Q1
$4.27M Sell
32,931
-901
-3% -$110K 0.25% 95
2018
Q4
$3.92M Sell
33,832
-1,724
-5% -$193K 0.26% 91
2018
Q3
$3.82M Buy
35,556
+2,018
+6% +$202K 0.23% 92
2018
Q2
$2.86M Sell
33,538
-1,589
-5% -$131K 0.18% 109
2018
Q1
$2.72M Buy
35,127
+1,048
+3% +$84.4K 0.18% 115
2017
Q4
$2.88M Sell
34,079
-338
-1% -$28.8K 0.19% 112
2017
Q3
$2.94M Sell
34,417
-941
-3% -$77.2K 0.2% 108
2017
Q2
$2.91M Sell
35,358
-133
-0.4% -$10.9K 0.21% 104
2017
Q1
$2.98M Buy
35,491
+68
+0.2% +$5.45K 0.23% 99
2016
Q4
$2.6M Buy
35,423
+25
+0.1% +$1.86K 0.22% 103
2016
Q3
$2.84M Sell
35,398
-1,404
-4% -$112K 0.25% 94
2016
Q2
$2.9M Buy
36,802
+181
+0.5% +$13.6K 0.27% 86
2016
Q1
$2.64M Sell
36,621
-897
-2% -$67.9K 0.26% 84
2015
Q4
$3.16M Sell
37,518
-1,370
-4% -$114K 0.33% 67
2015
Q3
$3.25M Sell
38,888
-440
-1% -$37.1K 0.37% 61
2015
Q2
$3.28M Sell
39,328
-2,411
-6% -$184K 0.35% 67
2015
Q1
$3.03M Buy
41,739
+347
+0.8% +$24.7K 0.32% 76
2014
Q4
$2.86M Buy
41,392
+679
+2% +$45.8K 0.32% 74
2014
Q3
$2.64M Buy
40,713
+66
+0.2% +$4.18K 0.3% 80
2014
Q2
$2.53M Buy
+40,647
New +$2.43M 0.29% 85

Other funds holding LLY

Capital Investment Advisors's LLY Position: Q1 2026 in Review

Capital Investment Advisors reduced its Eli Lilly (LLY) stake by 0.04% in Q1 2026, selling an estimated $11.2K and leaving 27,421 shares worth $25.2M. The position accounts for 0.37% of the portfolio, ranked #71.

Capital Investment Advisors first reported a position in LLY in Q2 2014 and has held it in 47 quarters since. The position peaked at $29.5M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Capital Investment Advisors held 27,421 shares of Eli Lilly worth $25.2M as of Q1 2026.
  • Capital Investment Advisors sold 11 Eli Lilly shares in Q1 2026, an estimated $11.2K.
  • Eli Lilly made up 0.37% of Capital Investment Advisors's portfolio in Q1 2026, its #71 holding.
  • Capital Investment Advisors first reported a position in Eli Lilly in Q2 2014 and has held it in 47 quarters since.
  • Capital Investment Advisors's Eli Lilly position peaked at $29.5M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Capital Investment Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.